Baltimore, May 7th-11th — GentiBio, a leading gene and cell therapy company specializing in engineered regulatory T cells, is set to share data from its first allogeneic Engineered Treg (EngTreg) program, GNTI-823, at the upcoming 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). With over 8000 attendees, the conference is the largest annual international gathering of cell and gene therapy professionals and features the latest groundbreaking scientific updates from the academic and drug development communities.
Three Key Presentations by GentiBio
- May 7th: An Allogeneic Engineered Tissue Treg Approach for the Treatment of Acute Ischemic and Inflammatory Diseases (Oral Abstract 39)
GentiBio introduces a novel approach for generating allogeneic Tissue Engineered Tregs (Tissue EngTregs) with enhanced tissue repair and inflammation reduction properties. Data highlighting the potential of these specialized cells in preclinical models of life-threatening diseases including ischemic stroke, acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) will be shared. This novel therapeutic approach holds promise for numerous and difficult to treat acute ischemic and inflammatory conditions. - May 8th: Adoptive Transfer of Allogeneic Murine Engineered T Regulatory Cells Ameliorates Disease in Models of Acute Kidney Injury in Mice (Oral Abstract 77) GentiBio shows the impact of adoptively transferred murine allogeneic engineered regulatory T cells (mEngTregs) in mitigating the severity of AKI and progression towards chronic kidney disease. By harnessing the power of Tissue Engineered Tregs, GentiBio aims to transform the approach to this common complication of cardiac surgery.
- May 10th: Characterization of Allogeneic Engineered Human Tissue-Tregs with Immune Suppression and Tissue Homing Capabilities for Treatment of Acute Inflammatory Diseases (Abstract #1809)
This presentation will encompass the characterization and mechanism of action of Tissue Engineered Tregs highlighting enhanced reparative function, tissue targeting, and immune regulation in response to inflammation. By precisely homing to the site of inflammation, GentiBio aims to provide an innovative and effective treatment for acute inflammatory diseases.
Scientific Impact and Future Prospects
GentiBio’s research seeks to advance the field of gene and cell therapy within the autoimmune and autoinflammatory spaces. By tailoring therapies to specific tissues and diseases, GentiBio aims to enhance patient outcomes and improve quality of life.
Dr. Thomas Wickham, Chief Scientific Officer at GentiBio, expressed enthusiasm about the upcoming conference: “Our work represents an exciting and promising way to leverage the ability of Tregs to home to sites of inflammation and promote tissue repair, thereby providing benefit to patients across multiple indications including stroke, acute kidney injury, and acute respiratory distress syndrome. We’re looking forward to sharing our findings with the scientific community and explore collaborative opportunities.”
Attendees of the ASGCT conference can catch these presentations during the oral abstract sessions or visit the poster hall to delve deeper into GentiBio’s research.
Stay tuned for more updates as GentiBio continues to push the boundaries of gene and cell therapy!
About GentiBio, Inc.
GentiBio, Inc. is a biotherapeutics company co-founded by pioneers in Treg biology and immunology from Seattle Children’s Research Institute, Benaroya Research Institute, and MIGAL Galilee Research Institute to develop engineered regulatory T cells programmed to treat autoimmune and inflammatory diseases. GentiBio’s Series A financing was led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, Novartis Venture Fund, and Seattle Children’s Research Institute. GentiBio’s autologous and allogeneic engineered Tregs platforms integrate key technologies designed to successfully (re)establish immune tolerance and overcome major limitations in existing Treg therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that has the potential to address the fundamental cause of many diseases that result from overactivity and/or malfunctioning of the immune system. The company also has a collaboration with Bristol Myers Squibb for the development of Treg therapies for inflammatory bowel diseases. To learn more, visit www.gentibio.com
Company Contact:
Chuck Silberstein
Chief Financial Officer
chuck.silberstein@gentibio.com